Uncharacterized MYH9 Germline Mutations in a Microcystic Adnexal Carcinoma Mimicker: Benign Deep Syringoid Ductal Proliferation (BDSDP) with Elastic Fiber Aggregation

preprint OA: closed
📄 Open PDF Full text JSON View at publisher
AI-generated deep summary by claude@2026-06, 2026-06-24 · read from full text

This case report investigated how previously uncharacterized heterozygous germline MYH9 variants relate to lesions that clinically and histologically mimic microcystic adnexal carcinoma, focusing on benign deep syringoid ductal proliferations with papillary dermal elastic fiber aggregation in a man in his 20s. Using histologic evaluation, immunohistochemistry for apocrine and basaloid myoepithelial markers, elastic tissue staining, and genetic/structural analyses with segregation testing in first-degree relatives, the authors found three heterozygous MYH9 missense variants (including two previously unreported) predicted to alter Myosin-9 coiled-coil structure, alongside dense papillary dermal elastic fiber aggregates and no perineural invasion. A major limitation is that the evidence is based on a single patient’s presentation and familial segregation plus in silico structural prediction rather than functional experiments. Relevance to endometriosis: the paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Importance Microcystic adnexal carcinoma (MAC) is a rare, locally aggressive sweat gland neoplasm sometimes misdiagnosed due to its histologic similarities to benign adnexal proliferations. MYH9-associated elastin aggregation syndrome (MALTA) is an inherited condition characterized by benign MAC-like ductal lesions and by abnormal elastic fiber deposition. Objective To report previously uncharacterized heterozygous germline mutations in the MYH9 gene in a patient presenting benign deep syringoid ductal proliferations and papillary dermal elastic fiber aggregation. Design, Setting, Participants Clinical report with genetic and structural analysis. Dermatology outpatient. A male in their 20’s presenting with long-standing, stable erythematous nodules on the right infraorbital region and left zygomatic arch. Genetic testing of first-degree relatives and structural simulations were performed to assess variant impact. Main Outcomes and Measures Histological evaluation of the patient’s lesions revealed benign deep syringoid ductal proliferations with papillary dermal elastic fiber aggregation, distinguishing them from microcystic adnexal carcinoma. Germline genetic testing identified three heterozygous MYH9 variants, two previously uncharacterized, all showing Mendelian segregation in first-degree relatives and associated with structural rearrangement. Results Histologic evaluation of the facial lesions revealed keratin-filled microcysts and deep dermal and subcutaneous cords with ductal structures resembling MAC. Immunohistochemistry showed apocrine differentiation (EMA+/CD15+/GCDP+) and basaloid myoepithelial cells positive for p63. No evidence of perineural invasion was observed. Elastic tissue staining showed dense, ball-like aggregates of elastic fibers in the papillary dermis. Germline testing identified c.1363G>A (p.Gly455Ser) in the myosin head domain, and c.4490G>A (p.Arg1497Gln) and c.4876A>G (p.Ile1626Val) in the tail domain of Myosin-9. Saliva-based testing confirmed Mendelian segregation in multiple first-degree relatives. Missense mutations were predicted to alter the coiled-coil structure, potentially disrupting chain interactions and affecting the motif’s parallel versus antiparallel orientation. Conclusions and Relevance This case broadens the phenotypic and genotypic spectrum of MALTA syndrome and introduces the diagnostic term: benign deep syringoid ductal proliferation (BDSDP) with elastic fiber aggregation. The findings underscore the diagnostic challenges in distinguishing BDSDP from MAC and highlight the critical role of integrating histopathologic, immunohistochemical, and genetic data in accurate diagnosis. These results support the need for further investigation into MYH9-associated adnexal neoplasia and its underlying molecular mechanisms. Key Points Question How do germline MYH9 variants contribute to the pathogenesis of benign deep syringoid ductal proliferations with elastic fiber aggregation, a phenotype that clinically and histologically mimics microcystic adnexal carcinoma? Findings Genetic analysis revealed two previously unreported heterozygous variants in the MYH9 gene: c.1363G>A (p.Gly455Ser), located in the myosin head domain, a region previously associated with MALTA syndrome, and a variant in the myosin tail domain, c.4490G>A (p.Arg1497Gln). A third mutation, c.4876A>G (p.Ile1626Val), was also detected. All three variants demonstrated Mendelian segregation from the parents, were identified in multiple family members, and were predicted to cause structural perturbations. Meaning These findings provide strong evidence for a heritable contribution of these mutations to the observed phenotype. The presence of these MYH9 variants highlights a potential functional impact on protein structure and activity. This pattern supports the hypothesis that MYH9 mutations may underlie or modify the pathogenesis of benign syringoid ductal proliferations, expanding the known spectrum of MYH9-associated conditions and offering a molecular basis for improved diagnosis and familial risk assessment.
Full text 5,938 characters · extracted from oa-doi-fallback · 4 sections · click to expand

Abstract

Importance Microcystic adnexal carcinoma (MAC) is a rare, locally aggressive sweat gland neoplasm sometimes misdiagnosed due to its histologic similarities to benign adnexal proliferations. MYH9-associated elastin aggregation syndrome (MALTA) is an inherited condition characterized by benign MAC-like ductal lesions and by abnormal elastic fiber deposition.

Objective

To report previously uncharacterized heterozygous germline mutations in the MYH9 gene in a patient presenting benign deep syringoid ductal proliferations and papillary dermal elastic fiber aggregation. Design, Setting, Participants Clinical report with genetic and structural analysis. Dermatology outpatient. A male in their 20’s presenting with long-standing, stable erythematous nodules on the right infraorbital region and left zygomatic arch. Genetic testing of first-degree relatives and structural simulations were performed to assess variant impact. Main Outcomes and Measures Histological evaluation of the patient’s lesions revealed benign deep syringoid ductal proliferations with papillary dermal elastic fiber aggregation, distinguishing them from microcystic adnexal carcinoma. Germline genetic testing identified three heterozygous MYH9 variants, two previously uncharacterized, all showing Mendelian segregation in first-degree relatives and associated with structural rearrangement.

Results

Histologic evaluation of the facial lesions revealed keratin-filled microcysts and deep dermal and subcutaneous cords with ductal structures resembling MAC. Immunohistochemistry showed apocrine differentiation (EMA+/CD15+/GCDP+) and basaloid myoepithelial cells positive for p63. No evidence of perineural invasion was observed. Elastic tissue staining showed dense, ball-like aggregates of elastic fibers in the papillary dermis. Germline testing identified c.1363G>A (p.Gly455Ser) in the myosin head domain, and c.4490G>A (p.Arg1497Gln) and c.4876A>G (p.Ile1626Val) in the tail domain of Myosin-9. Saliva-based testing confirmed Mendelian segregation in multiple first-degree relatives. Missense mutations were predicted to alter the coiled-coil structure, potentially disrupting chain interactions and affecting the motif’s parallel versus antiparallel orientation.

Conclusions

and Relevance This case broadens the phenotypic and genotypic spectrum of MALTA syndrome and introduces the diagnostic term: benign deep syringoid ductal proliferation (BDSDP) with elastic fiber aggregation. The findings underscore the diagnostic challenges in distinguishing BDSDP from MAC and highlight the critical role of integrating histopathologic, immunohistochemical, and genetic data in accurate diagnosis. These results support the need for further investigation into MYH9-associated adnexal neoplasia and its underlying molecular mechanisms. Question How do germline MYH9 variants contribute to the pathogenesis of benign deep syringoid ductal proliferations with elastic fiber aggregation, a phenotype that clinically and histologically mimics microcystic adnexal carcinoma? Findings Genetic analysis revealed two previously unreported heterozygous variants in the MYH9 gene: c.1363G>A (p.Gly455Ser), located in the myosin head domain, a region previously associated with MALTA syndrome, and a variant in the myosin tail domain, c.4490G>A (p.Arg1497Gln). A third mutation, c.4876A>G (p.Ile1626Val), was also detected. All three variants demonstrated Mendelian segregation from the parents, were identified in multiple family members, and were predicted to cause structural perturbations. Meaning These findings provide strong evidence for a heritable contribution of these mutations to the observed phenotype. The presence of these MYH9 variants highlights a potential functional impact on protein structure and activity. This pattern supports the hypothesis that MYH9 mutations may underlie or modify the pathogenesis of benign syringoid ductal proliferations, expanding the known spectrum of MYH9-associated conditions and offering a molecular basis for improved diagnosis and familial risk assessment. Competing Interest Statement Dr. Grider served on an advisory board for Castle Biosciences regarding melanoma prognostic testing. Dr. A. Brown holds shares in Beam Diagnostics, Inc., which is unrelated to the present work. All other authors report no conflicts of interest. Funding Statement This project was supported by funds from the Fralin Biomedical Research Institute at VTC to Finkielstein. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: IRB committee of Virginia Tech waived ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00